CR11730A - Compuestos de anillo fusionados y uso de los mismos - Google Patents
Compuestos de anillo fusionados y uso de los mismosInfo
- Publication number
- CR11730A CR11730A CR11730A CR11730A CR11730A CR 11730 A CR11730 A CR 11730A CR 11730 A CR11730 A CR 11730A CR 11730 A CR11730 A CR 11730A CR 11730 A CR11730 A CR 11730A
- Authority
- CR
- Costa Rica
- Prior art keywords
- fusioned
- same
- ring compounds
- agent
- prophylaxis
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Diabetes (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Child & Adolescent Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Enzymes And Modification Thereof (AREA)
- Compositions Of Macromolecular Compounds (AREA)
Abstract
La presente invencion proporciona un activador de glucocinasa util como un agente farmaceutico tal como un agente para la profilaxis o tratamiento de diabetes, obesidad y similares.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2008102691 | 2008-04-10 |
Publications (1)
Publication Number | Publication Date |
---|---|
CR11730A true CR11730A (es) | 2010-12-08 |
Family
ID=40671202
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CR11730A CR11730A (es) | 2008-04-10 | 2010-10-14 | Compuestos de anillo fusionados y uso de los mismos |
Country Status (35)
Country | Link |
---|---|
US (1) | US8673942B2 (es) |
EP (1) | EP2276760B1 (es) |
JP (1) | JP5528348B2 (es) |
KR (1) | KR20110002472A (es) |
CN (1) | CN102056924B (es) |
AR (1) | AR073609A1 (es) |
AU (1) | AU2009234666B2 (es) |
BR (1) | BRPI0910912A2 (es) |
CA (1) | CA2720686A1 (es) |
CO (1) | CO6321240A2 (es) |
CR (1) | CR11730A (es) |
CY (1) | CY1115247T1 (es) |
DK (1) | DK2276760T3 (es) |
DO (1) | DOP2010000301A (es) |
EA (1) | EA019640B1 (es) |
EC (1) | ECSP10010602A (es) |
ES (1) | ES2476265T3 (es) |
GE (1) | GEP20135846B (es) |
HK (1) | HK1152932A1 (es) |
HR (1) | HRP20140588T1 (es) |
IL (1) | IL208463A (es) |
MA (1) | MA32283B1 (es) |
ME (1) | ME01887B (es) |
MX (1) | MX2010011138A (es) |
MY (1) | MY152475A (es) |
NZ (1) | NZ588562A (es) |
PE (1) | PE20100734A1 (es) |
PL (1) | PL2276760T3 (es) |
PT (1) | PT2276760E (es) |
RS (1) | RS53378B (es) |
SI (1) | SI2276760T1 (es) |
UA (1) | UA104422C2 (es) |
UY (1) | UY32131A (es) |
WO (1) | WO2009125873A1 (es) |
ZA (1) | ZA201007682B (es) |
Families Citing this family (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8557805B2 (en) | 2008-12-29 | 2013-10-15 | Takeda Pharmaceutical Company Limited | Fused ring compound and use thereof |
WO2011107494A1 (de) | 2010-03-03 | 2011-09-09 | Sanofi | Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung |
US8530413B2 (en) | 2010-06-21 | 2013-09-10 | Sanofi | Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments |
TW201215387A (en) | 2010-07-05 | 2012-04-16 | Sanofi Aventis | Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament |
TW201221505A (en) | 2010-07-05 | 2012-06-01 | Sanofi Sa | Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament |
TW201215388A (en) | 2010-07-05 | 2012-04-16 | Sanofi Sa | (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments |
WO2013037390A1 (en) | 2011-09-12 | 2013-03-21 | Sanofi | 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
WO2013045413A1 (en) | 2011-09-27 | 2013-04-04 | Sanofi | 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
WO2014085486A2 (en) | 2012-11-30 | 2014-06-05 | Waters Technologies Corporation | Methods and apparatus for the analysis of vitamin d metabolites |
US9453038B2 (en) | 2012-12-17 | 2016-09-27 | Merck Sharp & Dohme Corp. | Glucokinase activator compounds, compositions containing such compounds, and methods of treatment |
Family Cites Families (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH05505612A (ja) | 1991-03-01 | 1993-08-19 | ハー・ルンドベック・アクティーゼルスカブ | 高血圧症及び末梢血管疾患の治療法 |
US6506901B2 (en) * | 2000-07-17 | 2003-01-14 | Wyeth | Substituted 2-(S)-hydroxy-3-(piperidin-4-yl-methylamino)-propyl ethers and substituted 2-aryl-2-(R)-hydroxy-1-(piperidin-4-yl-methyl)-ethylamine β-3 adrenergic receptor agonists |
CN101103977A (zh) * | 2002-06-05 | 2008-01-16 | 株式会社医药分子设计研究所 | 糖尿病治疗药 |
EP1532980A1 (en) | 2003-11-24 | 2005-05-25 | Novo Nordisk A/S | N-heteroaryl indole carboxamides and analogues thereof, for use as glucokinase activators in the treatment of diabetes |
WO2006089397A1 (en) | 2005-02-22 | 2006-08-31 | Gemin X Biotechnologies Inc. | Methods for treating arthritis using triheterocyclic compounds |
US8957070B2 (en) * | 2005-04-20 | 2015-02-17 | Takeda Pharmaceutical Company Limited | Glucokinase activator compounds, methods of activating glucokinase and methods of treating diabetes and obesity |
US7799820B2 (en) * | 2005-09-30 | 2010-09-21 | Banyu Pharmaceutical Co., Ltd. | 2-Heterocycle-substituted indole derivatives for treating diabetes and associated conditions |
BRPI0717722A2 (pt) | 2006-10-19 | 2013-10-29 | Takeda Pharmaceutical | Composto ou um sal do mesmo, pró-droga, ativador de glicoquinase, agente farmacêutico, métodos para ativar uma glicoquinase em um mamífero e para a profilaxia ou o tratamento de diabetes ou obesidade em um mamífero, e, uso do composto ou uma pró-droga do mesmo |
JP5323834B2 (ja) * | 2007-08-17 | 2013-10-23 | エルジー・ライフ・サイエンシーズ・リミテッド | 細胞壊死阻害剤としてのインドール化合物 |
KR101133772B1 (ko) * | 2007-12-20 | 2012-04-24 | 주식회사 엘지생명과학 | 글루코키나아제 활성화제 및 이를 활성성분으로 함유하는 약제학적 조성물 |
US20100291533A1 (en) * | 2008-01-04 | 2010-11-18 | Soon Ha Kim | Indole and indazole derivatives having a cell-, tissue- and organ-preserving effect |
US8557805B2 (en) * | 2008-12-29 | 2013-10-15 | Takeda Pharmaceutical Company Limited | Fused ring compound and use thereof |
-
2009
- 2009-04-09 CN CN200980121846.8A patent/CN102056924B/zh not_active Expired - Fee Related
- 2009-04-09 MY MYPI20104694 patent/MY152475A/en unknown
- 2009-04-09 PT PT97309306T patent/PT2276760E/pt unknown
- 2009-04-09 US US12/936,785 patent/US8673942B2/en not_active Expired - Fee Related
- 2009-04-09 AU AU2009234666A patent/AU2009234666B2/en not_active Ceased
- 2009-04-09 EP EP09730930.6A patent/EP2276760B1/en active Active
- 2009-04-09 RS RS20140324A patent/RS53378B/en unknown
- 2009-04-09 WO PCT/JP2009/057625 patent/WO2009125873A1/en active Application Filing
- 2009-04-09 SI SI200930911T patent/SI2276760T1/sl unknown
- 2009-04-09 ES ES09730930.6T patent/ES2476265T3/es active Active
- 2009-04-09 KR KR1020107025180A patent/KR20110002472A/ko not_active Application Discontinuation
- 2009-04-09 EA EA201071180A patent/EA019640B1/ru not_active IP Right Cessation
- 2009-04-09 JP JP2010538248A patent/JP5528348B2/ja not_active Expired - Fee Related
- 2009-04-09 BR BRPI0910912-9A patent/BRPI0910912A2/pt not_active IP Right Cessation
- 2009-04-09 PL PL09730930T patent/PL2276760T3/pl unknown
- 2009-04-09 CA CA2720686A patent/CA2720686A1/en not_active Abandoned
- 2009-04-09 ME MEP-2014-66A patent/ME01887B/me unknown
- 2009-04-09 DK DK09730930.6T patent/DK2276760T3/da active
- 2009-04-09 NZ NZ588562A patent/NZ588562A/en not_active IP Right Cessation
- 2009-04-09 MX MX2010011138A patent/MX2010011138A/es active IP Right Grant
- 2009-04-09 UA UAA201013332A patent/UA104422C2/uk unknown
- 2009-04-09 GE GEAP2009011998 patent/GEP20135846B/en unknown
- 2009-09-18 AR ARP090103590A patent/AR073609A1/es unknown
- 2009-09-21 UY UY0001032131A patent/UY32131A/es not_active Application Discontinuation
- 2009-09-30 PE PE2009001166A patent/PE20100734A1/es not_active Application Discontinuation
-
2010
- 2010-10-04 IL IL208463A patent/IL208463A/en not_active IP Right Cessation
- 2010-10-08 DO DO2010000301A patent/DOP2010000301A/es unknown
- 2010-10-14 CR CR11730A patent/CR11730A/es unknown
- 2010-10-27 ZA ZA2010/07682A patent/ZA201007682B/en unknown
- 2010-11-01 MA MA33304A patent/MA32283B1/fr unknown
- 2010-11-10 CO CO10140654A patent/CO6321240A2/es active IP Right Grant
- 2010-11-10 EC EC2010010602A patent/ECSP10010602A/es unknown
-
2011
- 2011-07-05 HK HK11106909.4A patent/HK1152932A1/xx not_active IP Right Cessation
-
2014
- 2014-06-23 HR HRP20140588AT patent/HRP20140588T1/hr unknown
- 2014-07-02 CY CY20141100499T patent/CY1115247T1/el unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CR11730A (es) | Compuestos de anillo fusionados y uso de los mismos | |
CR10748A (es) | Compuesto de indol | |
CL2011000691A1 (es) | Compuestos derivados de nicotinamida sustituida; composicion farmaceutica que los comprende; uso para el tratamiento y/o prevencion de cancer, infecciones, enfermedades inflamatorias y autoinmunitarias. | |
CL2007002890A1 (es) | Compuestos derivados de 2-piridincarboxamida, activador de glucosinasa; composicion farmaceutica; y uso del compuesto para el tratamiento de diabetes o la obesidad. | |
CL2007001869A1 (es) | Compuestos derivados de bencimidazol; procedimiento de preparacion; composiciones farmaceuticas; y uso para el tratamiento y/o profilaxis de enfermedades que se modulan con agonistas del fxr, tal como dislipidemias, diabetes, cancer, osteoporosis y e | |
CL2016001231A1 (es) | Compuestos de inhibidor de autotaxina | |
CL2012001762A1 (es) | Compuestos derivados de pirazina, con actividad inhibidora de bace; composicion farmaceutica que los comprende; y su uso para el tratamiento o la prevencion de enfermedad de alzheimer o deterioro cognitivo leve. | |
CL2012002771A1 (es) | Compuestos derivados de ariletinilo sustituidos, moduladores de los receptores mglur5; proceso de obtencion; composicion farmaceutica; y su uso en el tratamiento o prevencion de la esquizofrenia, enfermedades cognitivas, sindrome de x fragil o el autismo. | |
CL2012000921A1 (es) | Compuestos derivados de espiropiperidina-metilbenciloxifenil, activadores del receptor rpg-40; composicion farmaceutica que los comprende; y uso del compuesto para tratar diabetes. | |
CL2012003281A1 (es) | Uso de compuestos específicos estimuladores y/o activadores de sgc; formulacion farmaceutica que comprende dichos compuestos; kit que comprende los compuestos, y uso para la prevencion y/o tratamiento de la esclerosis sistematica. | |
CL2012002944A1 (es) | Compuestos derivados de amino-pirimidinas; composiciones farmacéuticas que los comprenden; y su uso para el tratamiento de una enfermedad afección seleccionada de trastornos neuromusculares, esclerosis lateral amiotrófica, miastenia grave, entre otras. | |
CL2012002945A1 (es) | Compuestos derivados de amino-piridazinas; composiciones farmacéuticas que los comprenden; y su uso para el tratamiento de una enfermedad afección seleccionada de trastornos neuromusculares, esclerosis lateral amiotrófica, miastenia grave, entre otras. | |
CL2013000304A1 (es) | Compuestos derivados de 2-arilamino-bencimidazoles inhibidores de prostaglandina e2 (mpges-1); composicion farmaceutica que los comprende; compuestos intermediarios; uso en el tratamiento de enfermedades inflamatorias y/o afecciones asociadas, en particular el dolor. | |
CL2012003415A1 (es) | Compuestos derivados de 2-oxo-piperidina y 1,1-dioxido-tiazina, inhibidores de mdm2; composicion farmaceutica que los comprende; y su uso para el tratamiento del cancer . | |
CL2008000946A1 (es) | Compuestos derivados de pirrolopirimidina, inhibidores de cianasa jak3; procedimiento de preparacion; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento de rechazo de transplantes, enfermedades autoinmun | |
MY153915A (en) | Organic compounds | |
MY155317A (en) | Benzene sulfonamide thiazole and oxazole compounds | |
CL2008002430A1 (es) | Compuestos derivados de bencenosulfonamida, inhibidores de catepsina c; composicion farmaceutica que los comprende; y su uso para el tratamiento de la epoc. | |
SV2009003307A (es) | Quinazolinas para la inhibicion de pdk1 | |
HN2010002478A (es) | Derivados de indazol sustituidos con fenilo y benzodioxinilo | |
CL2011001497A1 (es) | Compuestos derivados de heterociclos, modulador de gpr120; composicion farmaceutica; y su uso para el tratamiento de diabetes tipo i,ii y sindrome metabolico. | |
TR201900259T4 (tr) | Heterosiklik Bileşikler Ve Bunların Kullanımları | |
CL2015002698A1 (es) | Nuevos compuestos y composiciones para la inhibicion de fasn | |
CR11532A (es) | Formas cristalinas de dimetoxi-docetaxel y sus procedimientos de preparacion | |
CL2011000846A1 (es) | Compuestos heterociclicos sustituidos; composicion farmaceutica; y su uso para el tratamiento de la hepatitis c. |